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A B S T R A C T
 
Objective: The study aimed to investigate gyrA and gyrB mutations in Mycobacterium 
tuberculosis (MTB) clinical strains from 93 patients with pulmonary tuberculosis in Hubei 
Province, China, and analyze the association between mutation patterns of the genes and 
ofloxacin resistance level. 
Results: Among 93 MTB clinical isolates, 61 were ofloxacin-resistant by the proportion 
method, and 32 were ofloxacin-susceptible MDR-TB. No mutation in the gyrB gene was 
found in any MTB strains. In the 61 ofloxacin-resistant isolates, 54 mutations were 
observed in the gyrA gene. Only one mutation in the gyrA gene was found in ofloxacin-
susceptible MDR-TB isolates. In this study, the mutation patterns of gyrA involved seven 
patterns of single codon mutation (A90V, S91P, S91T, D94N, D94Y, D94G or D94A) and 
two patterns of double codons mutation (S91P & D94H, S91P & D94A). The ofloxacin minimal 
inhibitory concentrations (MICs) of three patterns of single codon mutations in the gyrA gene 
(codons 94, 90 and 91) showed a statistically significant difference (p < 0.0001). 
Conclusions: The gyrA mutations at codons 90, 91 and 94 constitute the primary mechanism 
of fluoroquinolone resistance in MTB, and mutations at codon 91 in the gyrA gene may be 
associated with low-level resistance to ofloxacin.
Introduction
Drug resistance of Mycobacterium tuberculosis is a major threat 
for the control of tuberculosis. Emergence of multidrug 
resistant tuberculosis (MDR-TB) and extensively drug resistant 
tuberculosis (XDR-TB) will be a challenge in the tuberculosis 
epidemic and will seriously impact therapeutic effect. 
According to a WHO report,1 an estimated 390,000-510,000 
cases of MDR-TB emerged globally in 2008. Among all incident 
TB cases globally, 3.6% were estimated to be MDR-TB. Almost 
50% of MDR-TB cases worldwide were estimated to occur in 
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China and India. In 2008, MDR-TB caused an estimated 150,000 
deaths all over the world.
Fluoroquinolones are potent second-line drugs recommended 
to treat MDR-TB.2 However, fluoroquinolone resistance among 
Mycobacterium tuberculosis strains is ever more prevalent.3,4 
In China, fluoroquinolones have been widely used for 
tuberculosis treatment and served routinely as monotherapy 
for the empirical treatment of numerous respiratory infections. 
Thus, China may be one of the countries with the highest 
rate of fluoroquinolone abuse and resistance.5 The patients 
suffering from MDR-TB would have a poor prognosis once 
Mycobacterium tuberculosis becomes resistant to ofloxacin.6 It 
has been reported that the new generation of fluoroquinolones, 
such as moxifloxacin and gatifloxacin, showed favorable 
pharmacokinetic activity and lower minimum inhibitory 
concentrations (MIC) against Mycobacterium tuberculosis.7,8 The 
main target of fluoroquinolones in Mycobacterium tuberculosis is 
the DNA gyrase, encoded by gyrA and gyrB.9 Mutations in two 
short regions known as quinolone-resistant determining regions 
(QRDRs) have been associated with fluoroquinolone resistance 
in Mycobacterium tuberculosis.
In the present study, we sequenced the QRDR in gyrA and 
gyrB genes of the MTB isolates from Hubei Province, China, and 
determined the MICs of ofloxacin, ciprofloxacin, moxifloxacin, 
and gatifloxacin. Further, we analyzed the possible correlation 
between gene mutations and resistance level to ofloxacin.
Methods
Bacterial isolates
A total of 93 MTB clinical isolates were collected from patients 
with pulmonary tuberculosis in Hubei Province, China from 
June 2009 to October 2010. These patients were epidemio-
logically unlinked. All MTB strains were identified by 
biochemical methods and real-time PCR detection based 
on primer derived from IS6110 (DAAN Gene – China). The oflox-
acin drug susceptibility test was performed by the proportion 
method (PM) on Lowenstein-Jensen (LJ) medium according to 
the standard procedure, with the breakpoint concentration of 
2 μg/mL for ofloxacin.10 Sixty-one ofloxacin-resistant MTB iso-
lates were selected and 32 ofloxacin-susceptible MDR-TB strains 
were also selected at random. Mycobacterium tuberculosis H37Rv 
(ATCC27294) was used as the reference control.
Determination of minimum inhibition concentrations (MICs) 
of four fluoroquinolones
The four fluoroquinolones included were: ofloxacin and 
ciprofloxacin (Sigma-Aldrich Co. – St Louis, USA), gatifloxacin 
(National Institutes for Food and Drug Control – China), and 
moxifloxacin (Bayer – Germany). Ciprofloxacin stock solutions 
were prepared at 1 mg/mL in distilled water; the three other 
fluoroquinolones were prepared at 1 mg/mL in 0.1 mmol/L 
NaOH, and sterilized using a 0.22 μm polycarbonate membrane 
filter (Corrighwohill, Co. Cork – Ireland). The stock solutions 
were stored at –70°C in small aliquots for up to six months. 
Frozen drug solutions were thawed once and then discarded.
MIC determinations of four quinolones were performed by 
using the resazurin colorimetric assay as described previously.11 
The final concentrations ranged from 0.06 μg/mL to 8 μg/mL. The 
MIC was determined by eyesight as the minimum drug concen-
tration that prevented the colour change in resazurin solution.
DNA extraction
A loopful of MTB culture from LJ medium was transferred to a 
1.5-mL tube that contained 1.0 mL sterilized water. The tube 
was centrifuged at 10,000×g for 5 min. The supernatant was 
discarded and the sediment was resuspended in 400 μL of TB 
lysating buffer (10 mmol/L Tris-HCl, 1 mmol/L EDTA [pH 8.0]), 
heat inactivated at 85°C for 30 min, and centrifuged at 10,000×g 
at 4°C for 10 min. The supernatant was transferred to another 
1.5-mL tube and preserved at –70°C until use.
PCR amplication of gyrA and gyrB genes
The primers for PCR amplification were designed with 
reference to gyrA and gyrB gene sequences (GenBank accession 
number L27512). The gyrA gene was amplified with the forward 
primer (5-ATCGAGCAGGAGATGCAG-3) and reverse primer 
(5-CGTCGTAGTTAGGGATGAAA-3). The gyrB gene was amplified 
using the forward primer (5-GTTTGAAGCCAACCCCACC-3) 
and reverse primer (5-TGAACCGGAACAACAACGT-3). The basic 
30-μL amplification reaction mixture containing 1.5 μL DNA, 
15 μL 2×PCR MIX (MBI Fermentas – Lithuania), 1.5 μL 2.5 μM PCR 
primer mixture (Sangon – Shanghai, China) and 12 μL distilled 
water. Cycling parameters were 5 min at 94°C, followed by 
30 cycles of 45 s at 94°C, 30 s at 56°C and 50 s at 72°C, followed 
by elongation at 72°C for 10 min. The PCR products of gyrA and 
gyrB were 415 bp and 470 bp in size, respectively.
Sequencing of QRDR of gyrA and gyrB genes
PCR products were purified with UNIQ-10 column purification 
kit (Sangon – Shanghai, China) and then sequenced with an 
automatic DNA sequencer (Applied Biosystems 3130xl DNA 
analyzer – USA). Mutations in gyrA and gyrB were identified 
using BLAST by comparison with Mycobacterium tuberculosis 
strain H37Rv sequence (GenBank accession number L27512).
Statistical analysis
The Statistical Package for Social Sciences (SPSS) version 
12.0 software (SPSS Inc. – Chicago, IL, USA) was used for the 
statistical analysis. The MICs of ofloxacin-resistant MTB 
clinical isolates with different mutations in the gyrA gene were 
compared by the analysis of variance (ANOVA) test. 
Results
Characterization of gyrA and gyrB mutations in ofloxacin-
sensitive and -resistant MTB isolates
Among the 93 MTB clinical isolates, 32 were ofloxacin-
susceptible and 61 were ofloxacin-resistant by the proportion 
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Strain isolates Mutation in gryA                                  MIC (μg/mL) of
    OFX CIP GAT MOX
19-7335 A90V 4 2 0.5 0.5
1-6974 A90V 4 4 0.25 0.5
5224 A90V 4 2 0.5 0.5
4462-3243 A90V 8 4 0.5 1
4706-4548 A90V 2 1 0.25 0.25
4740-4650 A90V 4 1 0.25 0.25
4802-4217 A90V 4 4 0.5 0.5
26-8519 A90V 2 1 0.125 0.125
9089 A90V 4 2 0.25 0.25
XN24 A90V 2 1 0.25 0.25
20-7378 S91T 2 1 0.25 0.125
4848-6374 S91P 2 1 0.25 0.25
9054 S91P 2 1 0.25 0.25
5304-1 S91P&D94H ≥ 16 ≥ 16 4 ≥ 16
19-8620 S91P&D94A ≥ 16 ≥ 16 8 ≥ 16
F10386 D94N 4 2 0.5 0.5
5357-2 D94N 8 ≥ 16 1 2
5375-1 D94N 2 1 0.125 0.25
4-7542 D94N 4 4 0.5 1
4410-2971 D94N 8 4 1 2
4-8283 D94N ≥ 16 8 2 2
5419 D94Y 8 8 0.5 1
4722-4743 D94Y 4 4 0.5 1
5363-1 D94Y 4 4 0.5 1
H59 D94Y 8 4 0.5 1
5416-1 D94G 4 4 0.25 0.25
17-7696 D94G 8 8 0.5 1
5240 D94G 8 4 1 2
5384 D94G 4 4 0.25 0.25
5342 D94G 8 4 0.5 0.5
5252-1 D94G 8 4 0.5 0.5
4542-3759 D94G 4 4 0.5 1
4686-4517 D94G 4 4 0.5 1
4702-4495 D94G 4 4 0.5 1
4795-6140 D94G 4 2 0.25 0.5
4868-6474 D94G 8 8 1 2
4897-6660 D94G 4 4 0.5 1
10-7928 D94G 8 4 0.5 1
5275-1 D94G 4 4 0.5 0.5
5288 D94G 4 4 0.25 0.5
5310-1 D94G 8 8 1 2
5330 D94G 4 2 0.5 0.5
YC29 D94G ≥ 16 8 1 2
YC38 D94G 8 8 2 2
YC41 D94G 16 8 2 4
YC43 D94G 8 8 1 1
9044 D94G ≥ 16 8 1 2
XN5 D94G 8 4 0.5 1
XN15 D94G 8 4 0.5 1
26-8700 D94G ≥ 16 ≥ 16 4 4
4863-6412 D94G 4 2 0.25 0.25
5359-2 D94A 8 ≥ 16 0.5 1
5441-2 D94A 4 4 0.5 0.5
YC60 D94A 4 2 0.5 1
8-7138 none 2 2 0.25 0.25
5-7427 none 2 1 0.25 0.25
5409-2 none 4 2 0.5 1
4435-3100 none 4 4 0.25 0.5
4862-6411 none 8 4 0.5 2
4927-6955 none 4 4 0.5 1
5296-1 none 8 4 1 2
No mutation was detected in gyrB gene. 
OFX, ofloxacin; CIP, ciprofloxacin; GAT, gatifloxacin; MOX, moxifloxacin. 
Table 1 - Mutations in gyrA and MICs determined by the resazurin colorimetric assay of 61 ofloxacin-resistant MTB 
isolates
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method on LJ medium. Among the 32 ofloxacin-susceptible 
MDR isolates, only one isolate had a D94N mutation, 
which had the ofloxacin MIC of 2 μg/mL, while the rest 
had no mutations. Among the 61 ofloxacin-resistant 
isolates, no mutation in gyrB was found, but 88.5% (54) 
had mutations observed in the gyrA gene. The results 
of mutations in gyrA and MICs of four fluoroquinolones, 
determined by the resazurin colorimetric assay for the 
61 ofloxacin-resistant isolates, are presented in Table 1. 
The 54 ofloxacin-resistant MTB isolates with gyrA 
mutation are summarized in Table 2. From Table 2, 
26 had a D94G mutation, six had a D94N mutation, four had 
a D94Y mutation, three had a D94A mutation, 10 had an 
A90V mutation, two had a S91P mutation, and one had a 
S91T mutation. Additionally, two strains with ofloxacin 
MIC ≥ 16 μg/mL had double mutations,  one with 
S91P&D94H, and the other with S91P&D94A. A S95T muta- 
tion in gyrA occurred in all MTB strains. No mutation in gyrB was 
detected in any of the MTB strains.
Association of the patterns of gyrA mutations and ofloxacin 
MICs profile of ofloxacin-resistant MTB isolates
The patterns of gyrA and the MICs of 54 ofloxacin-resistant 
MTB mutants were shown in Table 2. The ofloxacin MICs of 
isolates with mutations at codon 94 ranged from 2 μg/mL 
to 16 μg/mL, with a median of 8 μg/mL. The ofloxacin MICs 
of isolates with mutations at codon 90 ranged from 2 μg/mL 
to 8 μg/mL, with a median of 4 μg/mL. The ofloxacin MICs of 
isolates with mutations at codon 91 were all 2 μg/mL, with 
a median of 2 μg/mL. The difference in the ofloxacin MICs 
of four mutation patterns with different amino acid 
mutations at codon 94 (D94N, D94Y, D94G, D94A) in the 
QRDR of gyrA gene showed no statistical significance 
(p = 0.755). The ofloxacin MICs of three patterns with different 
single codon mutations in the gyrA gene (codons 94, 90 and 
91) were analyzed by ANOVA, which showed a statistically 
significant difference among the three groups (p < 0.0001).
MICs of four fluoroquinolones
The MICs of four fluoroquinolones of 61 ofloxacin-resistant 
MTB strains were determined by the resazurin colorimetric 
assay. The MIC50 and MIC90 values of the strains were 
summarized in Table 3. The MIC50 and MIC90 values for 
gatifloxacin and moxifloxacin were four to eight times lower 
than those for ofloxacin and ciprofloxacin.
Total No. of isolates Codon mutation  
patterns of gyrA
Nucleotide 
change
       No. of OFX-resistant isolates 
                MICs (μg/mL)
   2 4 8 16
26 D94G GAC→GGC 11 11 4
6 D94N GAC→AAC 1 2 2 1
4 D94Y GAC→TAC 2 2
3 D94A GAC→GCC 2 1
10 A90V GCG→GTC/GTG 3 6 1
2 S91P TCG→CCG 2
1 S91T TCG→ACG 1
1 S91P&D94H TCG→CCG&GAC→CAC 1
1 S91P&D94A TCG→CCG&GAC→GCC 1
OFX, ofloxacin.
Fluoquinolone MIC50 MIC90 Range of MIC
Ofloxacin 4 8 2 ∼ ≥ 16
Ciprofloxacin 4 8 1 ∼ ≥ 16
Gatifloxacin 0.5 1 0.125 ∼ 8
Moxifloxacin 1 2 0.125 ∼ ≥16
Table 2 - Patterns of gyrA mutations and ofloxacin MICs profile of ofloxacin-resistant MTB isolates 
Table 3 - MIC50 and MIC90 of four fluoroquinolones for 
61 ofloxacin-resistant MTB strains
Discussion
In the present study, gyrA mutations were predominantly 
found to occur in codons 90, 91, and 94, largely corroborating the 
findings of other studies.12-14 The strains isolated from Beijing, 
China, showed more double mutations,5 which indicated that 
mutations in the gyrA gene might vary in different regions. 
All MTB isolates had no mutation in the gyrB gene, which 
is in agreement with previous studies demonstrating that 
fluoroquinolone resistance of MTB are mostly attributed to 
the mutations of the gyrA gene, whereas gyrB mutations are 
rare.12,15,16 In the ofloxacin-resistant MTB clinical isolates, 54 
of 61 (88.5%) had mutations in the QRDR of the gyrA gene, 
and the other seven strains had no mutations in the gyrA 
and gyrB genes, a finding consistent with what has been 
previously reported on fluoroquinolone resistance.17 Other 
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resistance mechanisms, such as mutations in areas of gyrA 
or gyrB outside of the QRDR, decreased cell-wall permeability 
to the drug,18 and efflux pumps,19,20 probably accounting 
for the fluoroquinolone resistance in other fluoroquinolone-
resistant isolates without gyrA and gyrB mutations. Further 
studies are needed. The total mutation frequency of the gyrA 
gene in this study is similar to those of Shanghai (89.5%)12 
and Russia (83%),13 but higher than those of the Guangdong 
province (73.3%)16 and Taiwan (50%).3
Previous data suggested a four to 16-fold increase in MICs 
among laboratory mutants with a single gyrA mutation, 
compared to those of the parent strains, while the MICs 
increased 32-fold or more for mutants with double mutations.21 
In the present study, we reported two patterns of double 
mutations in two MTB clinical isolates; one with S91P&D94H, 
and the other with S91P&D94A. Previous reports on double 
mutations mainly focused on codons 90 and 94.14,21,22 The two 
MTB clinical isolates with double mutations had ofloxacin MIC 
≥ 16 μg/mL, and it indicated that these two patterns of double 
mutation were associated with high-level resistance, which is 
consistent with previous reports, where multiple mutations 
are associated with high-level resistance.22
Some studies have shown that the level of drug resistance 
of MTB was linked to gene mutations. Hauck et al.23 found 
that most rpoB gene mutations, such as codons 531 and 526, 
were correlated with high-level resistance to rifampin, and 
a lower level of resistance was associated with mutations 
at codons 511, 516, 533. Mutations at codon 315 of the katG 
gene were associated with high-level resistance to isoniazid, 
whereas mutations in the inhA gene or its promoter region 
were associated with low-level resistance to isoniazid.24 In 
the present study, we confirmed that mutations of gyrA 
constituted the primary mechanism of fluoroquinolone 
resistance in MTB; an analysis of relationship between 
different codon mutations in the gyrA gene and the MICs 
of ofloxacin-resistant MTB isolates by ANOVA showed 
a statistically significant difference. This suggested that 
mutations at codon 91 might develop low-level resistance to 
ofloxacin. Our report differed from the results of the study by 
Cui,12 which might be due to the different origin of the MTB 
isolates. Cheng17 also observed that the MICs of ofloxacin in 
mutations at codon 91 were lower than those at other codons 
such as 90 or 94. 
The newer generation of fluoroquinolones, such as 
moxifoxacin and gatifoxacin, was found to exhibit better 
activities than the other fluoroquinolones. Our results also 
showed that the MICs of moxifoxacin or gatifoxacin were 4- 
to 8-fold lower than those of ofloxacin or ciprofloxacin. For 
moxifoxacin and gatifoxacin, their superior activities have 
been attributed to the special structure-activity relationship of 
the C-8-methoxy and C-8-halogen substitution in the chemical 
structure of the prototype fluoroquinolones.25,26 These new 
members with  substitutions can have stronger bacteriostatic 
and lethal activities against MTB, as shown by their lower 
MICs even among the gyrA mutants.14,15 In addition, acquired 
resistance to these new drugs would be expected to develop 
less readily, as reflected by their lower mutant prevention 
concentrations.27 Recently, a murine model study showed 
that moxifloxacin was active against MTB strains with low-
level fluoroquinolone resistance and reduced the mortality 
associated with MTB strains with intermediate resistance.28 
Moxifloxacin and gatifloxacin could be used to treat low-level 
ofloxacin-resistant MDR-TB. Clinical trials should be conducted 
to confirm this observation.
In conclusion, we confirm that mutations of gyrA 
codons 90, 91 and 94 constituted the primary mechanism of 
fluoroquinolone resistance in MTB and indicate that mutations 
at codon 91 in gyrA gene might be associated with low-level 
resistance of ofloxacin.
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